



Sanofi Appoints Dr. Gary J. Nabel as Chairman of the *Strategic Development and Scientific Advisory Council*

Paris, France - January 7, 2013 - Sanofi (EURONEXT : SAN ; NYSE : SNY) is pleased to announce today the appointment of **Dr. Gary J. Nabel**, M.D., Ph.D., to Chairman of the *Strategic Development and Scientific Advisory Council (SDSAC)*.

Dr. Nabel, currently Senior Vice President, Chief Scientific Officer and Deputy to Dr. Elias Zerhouni, President, Global R&D, will succeed Dr. Richard Klausner. As part of his key responsibilities as Chief Scientific Officer for global R&D, Dr. Nabel will direct the activities of the Council, including selection, appointment and evaluation of advisers.

"I am delighted that Dr. Gary Nabel will continue to make this Council a vital part of our efforts to open Sanofi's research and development to outside perspectives", said Dr. Elias Zerhouni, President, Global R&D, Sanofi. *"I also wish to recognize and warmly thank Dr. Richard Klausner who has been an outstanding adviser to the Council. Under his leadership and invaluable experience, he has played a key role in setting out the role and composition of a group of experienced and internationally recognized advisers."*

Created in November 2010, the Council is a unique structure developed to enhance scientific discovery in a collaborative approach and to further develop a truly world-class research and development platform for future innovation for the benefit of patients around the world. The role of the Council is to advise Sanofi on new and emerging areas of science and technology as well as deepen Sanofi relationship with the external scientific world by creating a strong network of scientists and institutional partnerships. Dr. Richard Klausner occupied this position since March 1, 2011, providing overall direction and scientific leadership together with some of the most talented scientists around the world across the continuum from Discovery to Development to Delivery.

Dr. Gary J. Nabel Biography

Dr. Nabel has an extensive and distinguished background of academic and hospital appointments, and committee memberships including numerous prestigious awards and honors and an extensive publication record. He graduated magna cum laude from *Harvard College* in 1975 and continued his graduate studies at *Harvard University*, completing his Ph.D. in 1980 and his M.D. in 1982. He served as a postdoctoral fellow in the laboratory of David Baltimore at *MIT's Whitehead Institute*. Before his appointment at the *Vaccine Research Center*, Dr. Nabel served as the Henry Sewall Professor of Internal Medicine, Professor of Biochemistry, and Howard Hughes Medical Institute Investigator at the *University of Michigan in Ann Arbor*. In addition to his faculty positions, Dr. Nabel also served as the Director of the *Center for Gene Therapy* and co-director of the *Center for Molecular Medicine at the University of Michigan*. In recognition of his expertise at the forefront of virology, immunology, gene therapy, and molecular biology, Dr. Nabel was elected as a member of the *Institute of Medicine* of the *National Academy of Sciences* in 1998.

Dr. Richard Klausner Biography

Dr. Klausner is the former Executive Director for Global Health of the Bill and Melinda Gates Foundation. He was Director of the National Cancer Institute (NCI) between 1995 and 2001. He is currently partner at the Column Group, a San Francisco based venture firm. His research has been recognized with awards including the Outstanding Investigator Award from the American Federation of Clinical Research and the William Damashek Prize for major discoveries in haematology. He



received the 1997-1998 Dickson Prize in Medicine and the 1998 Raymond Bourguine Award. He has served as an Advisor to the Presidents of the Academies on counterterrorism and as Liaison to the White House Office of Science & Technology Policy. He is a member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Klausner is a past president of the American Society of Clinical Investigation and has been Chairman of the National Science Education Standards Projects of the National Academy of Sciences.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:

Media Relations

Jean-Marc Podvin

Tel.: + (33) 1 53 77 46 46

mr@sanofi.com

Investor Relations

Sébastien Martel

Tel.: + (33) 1 53 77 45 45

ir@sanofi.com